Skip to main content

Table 4 Incidence of signs, symptoms, and events in the past 12 months

From: Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review

Sign, symptom, or event, n (%) Currently using HU therapy (n = 1080) Discontinued HU therapy (n = 229)
Fatigue or tiredness 304 (28.1) 74 (32.3)
Splenomegaly 267 (24.7) 60 (26.2)
Plethora 138 (12.8) 27 (11.8)
Dizziness 112 (10.4) 41 (17.9)*
Headache 108 (10.0) 23 (10.0)
Abdominal discomfort/pain 106 (9.8) 39 (17.0)*
Hepatomegaly 103 (9.5) 27 (11.8)
Pruritus 96 (8.9) 23 (10.0)
Feeling of fullness 89 (8.2) 28 (12.2)
Thrombotic eventsa 64 (5.9) 11 (4.8)
Cardiovascular problems 52 (4.8) 14 (6.1)
Bone pain 43 (4.0) 16 (7.0)*
Anemia 28 (2.6) 13 (5.7)*
Thrombophlebitis 24 (2.2) 3 (1.3)
Thrombosis 22 (2.0) 2 (0.9)
Neutropenia 21 (1.9) 3 (1.3)
Thrombocytopenia 14 (1.3) 4 (1.8)
Stroke/TIA 18 (1.7) 5 (2.2)
Pulmonary embolism 7 (0.6) 1 (0.4)
Cancer 5 (0.5) 0
Elevation in blasts 2 (2.1) 4 (1.8)
Unknown 21 (1.9) 12 (5.2)*
No new symptoms 471 (43.6) 91 (39.7)
  1. HU hydroxyurea, TIA transient ischemic attack
  2. Values in italics identify signs, symptoms, or events that were significantly (P < 0.05) different between patients currently using HU therapy and those who discontinued HU therapy
  3. * P0.05
  4. aIncludes all patients who experienced pulmonary embolism, stroke/TIA, thrombophlebitis, and/or thrombosis; patients may have experienced more than 1 thrombotic event